End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26.77 CNY | -0.34% | -4.22% | +28.21% |
Mar. 25 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
Mar. 22 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.21% | 2.3B | - | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600750 Stock
- Ratings Jiang Zhong Pharmaceutical Co.,Ltd